Table 4

Predictive relevance of TP53 in breast cancer

AuthorYearNo.Stage of diseaseTechnique% abnormalTreatmentPredictive
Endocrine therapy1435
Bergh1995298PrimarycDNA sequencing22%Adjuvant TAMa and RTResistant
Archer199592AdvancedIHC58%HormonalNo
Silvestrini1996240PrimaryIHC14%Adjuvant TAMResistant
Elledge1997202MetastaticIHC20%TAMNo
Berns1998401MetastaticLIAMedianTAMResistant
Berns2000202MetastaticcDNA sequencing32%TAMResistant
(this study)
Chemoendocrine therapy341
Elledge1995261PrimaryIHC38%Adjuvant chemo (CMF & prednisone)No
Markris199780PrimaryIHC39%Neoadjuvant chemo and TAMNo
Chemo3428
Jacquemier199481PrimaryIHC39%Adjuvant chemoNo
Faille199438Loc advancedPCR-SSCP sequencing36%ChemoResistant
Muss1994394PrimaryIHC35%Adjuvant chemoNo
Stål1995139PrimaryIHC14%Adjuvant chemoSensitive
Aas199663Loc advancedIHC???Doxorubicin monotherapyNo
Aas199663Loc advancedCDGE/cDNA sequencing29%Doxorubicin monotherapyResistant
MacGrogan1996125PrimaryIHC27%Neoadjuvant chemoNo
Linn199770PrimaryIHC65%/30%Neoadjuvant chemo high dose & GM-CSFNo
Dublin1997277PrimaryIHC21%Adjuvant CMFNo
Niskanen1997103MetastaticIHC16%FECNo
Bonetti199843MetastaticIHC51%CMF/CA-EFNo
Rozan1998329PrimaryIHC38%Neoadjuvant chemoNo
Degeorges1998277PrimaryIHC24%Adjuvant chemoNo
Clahsen1998440PrimaryIHC18%FAC, one course perioperativeResistant
Järvinen199855AdvancedIHC33%Epirubicin monotherapyNo
Thor1998994PrimaryIHC33%Adjuvant CAF dose intensiveSensitive
Radiotherapy781
Jansson1995168PrimarycDNA-based sequence18%Adjuvant locoregional RTSensitive
Silvestrini1997613PrimaryIHC18%Adjuvant RTSensitive
  • a TAM, tamoxifen; RT, radiotherapy; chemo, chemotherapy; GM-CSF, granulocyte macrophage colony-stimulating factor; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; CA-EF, cyclophosphamide Adriamycin-epirubicin 5-fluorouracil; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; Loc, local; SSCP, single strand conformational polymorphism; CDGE, constant denaturing gel electrophoresis.